6:28 PM
 | 
Jan 15, 2013
 |  BC Extra  |  Company News

Santarus gains on Uceris approval, 2013 guidance

Santarus Inc. (NASDAQ:SNTS) gained $1.24 (11%) to $12.52 on Tuesday after FDA approved Uceris budesonide late Monday to induce remission of mild to moderate active ulcerative colitis (UC). The...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >